BioCryst Pharmaceuticals BCRX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's total current liabilities?
- BioCryst Pharmaceuticals (BCRX) reported total current liabilities of $195.39M in Q1 2026.
- How has BioCryst Pharmaceuticals's total current liabilities changed year-over-year?
- BioCryst Pharmaceuticals's total current liabilities increased by 39.7% year-over-year, from $139.86M to $195.39M.
- What is the long-term trend for BioCryst Pharmaceuticals's total current liabilities?
- Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's total current liabilities has grown at a 13.2% compound annual growth rate (CAGR), from $105.65M to $196.07M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.